{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:15:37Z","timestamp":1792278937576,"version":"4.4.0"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,8,15]]},"DOI":"10.2169\/internalmedicine.0789-22","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T22:10:44Z","timestamp":1673475044000},"page":"2301-2306","source":"Crossref","is-referenced-by-count":12,"title":["A Vonoprazan, Clarithromycin, and Metronidazole Regimen as &lt;i&gt;Helicobacter pylori&lt;\/i&gt; Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance"],"prefix":"10.2169","volume":"62","author":[{"given":"Kazunori","family":"Adachi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Koshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshimine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Izawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Clinical Research Center, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Ebi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Funaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Kasugai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Malfertheiner P, Megraud F, O&apos;Morain CA, et al. Management of <i>Helicobacter pylori<\/i> infection - the Maastricht V\/Florence Consensus Report. Gut 66: 6-30, 2017.","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Graham DY, Fischbach L. <i>Helicobacter pylori<\/i> treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010.","DOI":"10.1136\/gut.2009.192757"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of <i>Helicobacter pylori<\/i> infection: which regimen first? World J Gastroenterol 20: 665-672, 2014.","DOI":"10.3748\/wjg.v20.i3.665"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of <i>Helicobacter pylori<\/i> strains in Japan between 2002 and 2005. J Clin Microbiol 45: 4006-4010, 2007.","DOI":"10.1128\/JCM.00740-07"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of <i>Helicobacter pylori<\/i> antibiotic resistance. Aliment Pharmacol Ther 43: 514-533, 2016.","DOI":"10.1111\/apt.13497"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Muranaka M, Okumura H, Takeda K, Koizumi K, Igarashi H. Population studies on drug hypersensitivities. Acta Allergol 28: 50-61, 1973.","DOI":"10.1111\/j.1398-9995.1973.tb02565.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Macy E. Penicillin and beta-lactam allergy: epidemiology and diagnosis. Curr Allergy Asthma Rep 14: 476, 2014.","DOI":"10.1007\/s11882-014-0476-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med 381: 2338-2351, 2019.","DOI":"10.1056\/NEJMra1807761"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kato M, Ota H, Okuda M, et al. Guidelines for the management of <i>Helicobacter pylori<\/i> infection in Japan: 2016 Revised Edition. Helicobacter 24: e12597, 2019.","DOI":"10.1111\/hel.12597"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of <i>Helicobacter pylori<\/i> eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 22: e12374, 2017.","DOI":"10.1111\/hel.12374"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-year first-line eradication rate of <i>Helicobacter pylori<\/i> based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 47: 53-58, 2010.","DOI":"10.3164\/jcbn.10-10"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. <i>Helicobacter pylori<\/i> first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 22: 1041-1046, 2005.","DOI":"10.1111\/j.1365-2036.2005.02687.x"},{"key":"13","unstructured":"13. Nyssen OP, P\u00e9rez-Aisa \u00c1, Tepes B, et al; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on <i>H pylori<\/i> management (Hp-EuReg). Helicobacter 25: e12686, 2020."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility-guided therapy for <i>Helicobacter pylori<\/i>-infected penicillin-allergic patients: a prospective clinical trial of first-line and rescue therapies. Helicobacter 25: e12699, 2020.","DOI":"10.1111\/hel.12699"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shinmura T, Adachi K, Yamaguchi Y, et al. Vonoprazan-based triple-therapy could improve efficacy of the tailored therapy of <i>Helicobacter pylori<\/i> infection. J Gastrointestin Liver Dis 28: 389-395, 2019.","DOI":"10.15403\/jgld-222"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shimoyama T, Chinda D, Sawada Y, et al. Randomized trial comparing esomeprazole and rabeprazole in first-line eradication therapy for <i>Helicobacter pylori<\/i> infection based on the serum levels of pepsinogens. Intern Med 56: 1621-1627, 2017.","DOI":"10.2169\/internalmedicine.56.7823"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Okimoto T, Mizukami K, Ogawa R, et al. Esomeprazole- or rabeprazole-based triple therapy eradicated <i>Helicobacter pylori<\/i> comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes. J Clin Biochem Nutr 59: 149-153, 2016.","DOI":"10.3164\/jcbn.16-18"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Lind T, Veldhuyzen van, Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1: 138-144, 1996.","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for <i>Helicobacter pylori<\/i> eradication. Intern Med 59: 153-161, 2020.","DOI":"10.2169\/internalmedicine.2521-18"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. <i>Helicobacter pylori<\/i> rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open 5: 307-311, 2021.","DOI":"10.1002\/jgh3.12492"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sue S, Suzuki N, Shibata W, et al. First-line <i>Helicobacter pylori<\/i> eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin. Gastroenterol Res Pract 2017: 2019802, 2017.","DOI":"10.1155\/2017\/2019802"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41: 636-648, 2015.","DOI":"10.1111\/apt.13121"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol 6: e94, 2015.","DOI":"10.1038\/ctg.2015.18"},{"key":"24","unstructured":"24. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and <i>Helicobacter pylori<\/i>. Yale J Biol Med 69: 301-316, 1996."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sachs G, Scott DR, Wen Y. Gastric infection by <i>Helicobacter pylori<\/i>. Curr Gastroenterol Rep 13: 540-546, 2011.","DOI":"10.1007\/s11894-011-0226-4"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Scott D, Weeks D, Melchers K, Sachs G. The life and death of <i>Helicobacter pylori<\/i>. Gut 43: S56-S60, 1998.","DOI":"10.1136\/gut.43.2008.S56"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for <i>Helicobacter pylori<\/i> infection in the United States and Europe: randomized clinical trial. Gastroenterology 163: 608-619, 2022.","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line <i>Helicobacter pylori<\/i> treatment: a multicentre randomised trial in Japan. Gut 69: 1019-1026, 2020.","DOI":"10.1136\/gutjnl-2019-319954"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/16\/62_0789-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:21:37Z","timestamp":1692415297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/16\/62_0789-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0789-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"article-number":"0789-22"}}